Announcement
Announcement On ESG Ratings 13 Oct - CRISIL ESG Ratings assigned Supriya Lifescience a ‘CRISIL ESG 65’ score in the ‘Strong’ category.
Source: Bse
Supriya Lifescience Limited (SUPRIYA)
Micro CapPharma stocks · Micro cap · NSE
Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics with 40+ APIs. Diversified operations across 120+ countries, with 81% Q1FY27 revenue from exports. Manufacturing facility spread across 35,000 Sq.mts with 932 KLPD reactor capacity.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals17 Oct 2026 · screener
Latest result13 Aug, 06:48 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
76BullishSMA20 +8.0% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SUPRIYAD candles · FIT view+35.8%Latest close ₹873.25 on 2026-10-19
Bar
-1.8%
RSI
46
MACD hist
-7.57
52W pos
61%
2026-10-19O ₹889.10H ₹904.90L ₹867.70C ₹873.25Vol 2.0L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SUPRIYANifty PharmaNifty 500
- SUPRIYA
- +4.3%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +9.9 pp
Chart stats
19 Oct 2026- From 52W high
- -19.5%
- 52W range position
- 61%
- ATR (14)
- 4.2%
- Volume vs 20D
- 0.67x
- Avg traded value
- ₹28.3 Cr
- 20D price channel
- ₹839.9 - ₹1,019.8
₹1,085
₹545.5 - ₹1,085
₹36.9
Latest completed session
20-session average
46.4% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · FAIR VALUE52
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +31.0% · PAT -31.4% YoY
Technical
Bullish76
Price trend and sector-relative-strength timing.
Valuation
Legacy model+19.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence84
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -31% YoY · margin compression · Rev +31% YoY
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹190 Cr | +31.0% | -31.4% |
| EBITDA | ₹47 Cr | -9.6% | -52.0% |
| Operating margin | 25.0% | -1100 bps | -1000 bps |
| PAT | ₹24 Cr | -31.4% | -67.6% |
| PAT margin | 12.6% | -1151 bps | -1408 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 35.90
- P/B
- 5.95
- EV/EBITDA
- 22.22
- Market Cap
- 7129.00Cr
Profitability
- ROE
- 19.10%
- ROCE
- 25.20%
- ROA
- 14.59%
- Dividend Y
- 0.11%
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 11.00%
- Revenue 3Y
- 22.00%
- EPS 3Y
- 32.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- 145.00×
- Altman Z
- 8.89
- Book Value
- 149.00
Cash Flow
- FCF Yield
- 0.14%
- FCF Positive Y
- 6/5
- OCF
- 186.00 Cr
- EPS TTM
- 24.65
Shareholding
- Promoter Hold
- 68.30%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 63%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 190-31.4% vs prev
Net Profit
₹ CrLatest: 24.0-67.6% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term uptrend intact. RSI 46.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~7.4% over last month) — short-term momentum positive.
- RSI(14) at 46 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 20% off 52W high · 60% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
79
RS percentile
Stage 2 UptrendEstablished S2
1M return
-3.6%
3M return
+4.3%
6M return
+33.1%
1Y return
+16.5%
RS 1D
-2
RS 20D
+1
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 7.1% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +5.1%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
05 Jun 2026
S2 age
95 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 128.18-0.42%
RS vs Nifty 500128
Valuation & peers
U-Score 52 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 52 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation5/30
Growth13/25
Quality14/20
Balance Sheet11/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
52
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
52/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 19.4%.
- Balance sheet contributes 11/15 to the score.
Main drags
- Valuation is weaker at 5/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Growth is weaker at 13/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
35.9
PB
6.0
EV/EBITDA
22.2
ROE
19.1%
ROCE
25.2%
FCF Yield
0.1%
Debt/Equity
0.0
MoS
+19.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
52
Previous: 52
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+19.4%
Previous: +19.4%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
52
53
53
53
53
53
52
52
52
52
52
52
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹287.47
-203.8% MoS
Growth-justified P/E
44.0
Growth-justified Value
₹1,084.11
+19.4% MoS
PEG
2.04
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SPARC
Micro
Sun Pharma Advanced Research Company Limited
Healthcare Services
match 166
56
3.8
279.0%
+11%
FAIR VALUE
YATHARTH
Micro
Yatharth Hospital & Trauma Care Services Limited
Healthcare Services
match 163
37
52.6
10.2%
-15%
WATCHLIST
STAR
Micro
Strides Pharma Science Limited
Healthcare Services
match 163
69
16.6
20.0%
+65%
UNDERVALUED
SUDEEPPHRM
Micro
Sudeep Pharma Limited
Healthcare Services
match 161
49
65.4
25.2%
-32%
FAIR VALUE
KOVAI
Small
Kovai Medical Center & Hospital Limited
Healthcare Services
match 161
46
113.0
22.2%
-146%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis under stressReviewed 2026-10-12T08:16:23.632Z
Management commentary snapshot
Q1 FY27 Revenue grew 31% YoY to INR 1,897.5 Mn, but EBITDA declined 8% YoY to INR 474.6 Mn. PAT fell 31% YoY to INR 240.4 Mn, with significant margin contraction.
While revenue growth is robust YoY, the sharp decline in profitability, both YoY and QoQ, is a major concern. Significant increase in Cost of Goods Sold has eroded margins, raising questions about cost control and pricing power. Sequential performance also shows a steep drop.
Current business mix
Revenue Contribution – By Region (Q1 FY27)
Latest issuer-disclosed distribution across 5 reported categories.
Asia39.0%
Europe35.0%
LATAM20.0%
North America3.0%
Others3.0%
Growth engines
New Product Launches
Launch of three molecules including Liquid Anesthesia in 2025. Planning ~2 launches each in Anesthetic and ADHD to deepen the pipeline and drive growth in FY27.
Backward Integration
20 products are backward integrated, driving 72% of Q1FY27 revenue, enabling revenue growth while sustaining margins.
New Market Penetration
Penetration of existing products to newer geographies by registering these products.
CMO/CDMO Opportunities
Evaluating opportunity for exclusive manufacturing rights in liquid inhalation products. Multiple opportunities under active negotiation for finished dosage development and supply.
Capacity and execution
New Vitamin Product Block
New vitamin product block successfully commissioned.
Debottlenecking & New F Block
Civil work initiated for debottlenecking across all production blocks for capacity enhancement and new F block will be added.
New Production Block at Lote
Capacity expansion planned with addition of a new production block at Lote.
New Nasal Line
New nasal line planned to strengthen finished dosage capabilities.
Tailwinds
Diversified Geographic Presence
Presence in 120+ Countries Across Globe, with low dependence on a specific geography.
Strong Regulatory Compliance
50+ Registrations in different countries, 21 USDMF’s, 14 CEPs.
R&D Focus
Two R&D centres (Ambernath for Formulations/Generic APIs, Lote for Lifecycle improvement) with ongoing efforts to add 3-4 products every year.
Headwinds
Increased Cost of Goods Sold
Cost of Goods Sold increased 77.5% YoY, significantly outpacing revenue growth.
Margin Contraction
EBITDA % declined 1,063 bps YoY and PAT % declined 1,131 bps YoY.
Risk radar
Profitability Pressure
Significant YoY and QoQ decline in EBITDA and PAT margins indicates pressure on profitability, potentially from rising input costs or pricing pressures.
Customer Concentration
Share of top 10 customers was 52% in FY26, though management plans to reduce it.
Execution Risk for New Launches
Success of planned ~2 launches each in Anesthetic and ADHD, and 30 products under development, is crucial for future growth.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
YoY comparison is crucial for understanding underlying business growth and seasonal trends. QoQ is important to assess sequential momentum and the sharp decline in profitability and revenue from Q4 FY26.
Sector KPIs management disclosed
Revenue from Operations
INR 1,897.5 Mn, +30.8% YoY, -31.4% QoQ
EBITDA
INR 474.6 Mn, -8.2% YoY, -51.4% QoQ
EBITDA %
25.0%, -1,063 bps YoY, -1,029 bps QoQ
PAT %
12.7%, -1,131 bps YoY, -1,417 bps QoQ
Management forward view
API R&D Expansion
Ambernath API R&D facility fully commissioned with 16 scientists, capable of developing 3–4 APIs annually.
Finished Dosage R&D Pipeline
30 products under development across various dosage forms, with five exhibits completed and progressing towards 10.
New Market Expansion
Expanded API customer base across Japan, EU, and US; regulatory filings in EU and US underway.
Dossier Filings
Plan to file six dossiers in the EU during the current financial year.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| EBITDA Margin | 25.0% (Q1 FY27) | Stabilization or improvement from current depressed levels, indicating cost control and pricing power. |
| New Product Launches | 3 molecules launched in 2025, ~2 planned each in Anesthetic and ADHD for FY27. | Timely launch and commercial success of new molecules and finished dosage products. |
| Cost of Goods Sold Trend | Increased 77.5% YoY in Q1 FY27. | Moderation in COGS growth relative to revenue, indicating better cost management or input price stability. |
| Capacity Utilization | 70% (Q1 FY27) | Ramp-up of new capacities and sustained healthy utilization across all blocks. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
84Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 97th percentile of the scored universe and 95th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
75 docs text-extracted · 32 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
97th percentile
overall median 67 · Pharma: 95th pctile, median 70 · Micro: 95th pctile, median 73
Evidence depth
Financial-only
75 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
72
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 68.3%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.2%.
- ▸5 years of positive FCF.
Trust risks
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Supriya Lifescience Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 23 Sep - Bombay High Court allows provisional release of 200 kg Ketamine Hydrochloride on ₹72 lakh deposit.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 20 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Sep - Intimation of Investor/ Analyst Call is enclosed herewith. Kindly take the same on record.
Source: Bse
Annual report
Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Sep - Copy of Newspaper Public for dispatch of AGM Notice and Annual Report.
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 4 Jul - On July 3, 2026, Customs initiated NDPS proceedings against GM Sreekant Sreedharan; custody till July 17.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Aug - Enclosed herewith Copy of Newspaper Publication of Results for quarter ended June 30, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 13 Aug - Supriya Lifescience reported Q1 FY27 revenue of Rs 189.75 crore, up 30.8%; Ambernath finished dosage facility commissioned.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Jun - Intimation of Analyst / Investor Meeting is enclosed herewith.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9 Jun
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.